Sinotherapeutics Inc. A Total Liabilities

Latest as of March 2026: CN¥145.56 Million CNY ≈ $21.30 Million USD

Sinotherapeutics Inc. A total liabilities. Based on the latest financial reports, Sinotherapeutics Inc. A (688247) has total liabilities worth CN¥145.56 Million CNY (≈ $21.30 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Sinotherapeutics Inc. A to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Sinotherapeutics Inc. A (2020–2025)

Total liabilities of Sinotherapeutics Inc. A from 2020 to 2025. This chart illustrates how Sinotherapeutics Inc. A's total liabilities have evolved over time, based on quarterly financial data.

Sinotherapeutics Inc. A Competitors by Total Liabilities

The table below lists competitors of Sinotherapeutics Inc. A ranked by their total liabilities.

Company	Country	Total Liabilities
Grenke AG XETRA:GLJ	Germany	€7.40 Billion
National Petroleum Co Ltd TW:9937	Taiwan	NT$7.41 Billion
Shanghai Phoenix Enterprise Group Co Ltd A SHG:600679	China	CN¥1.14 Billion
Tungkong Inc SHE:002117	China	CN¥513.22 Million
Oron Group Investments & Holdings Ltd TA:ORON	Israel	ILA1.81 Billion
Viyash Scientific Limited NSE:SEQUENT	India	Rs8.40 Billion
Hanwha Investment&Securities Co Ltd KO:003530	Korea	₩19.36 Trillion
Pagerduty Inc NYSE:PD	USA	$719.85 Million

Liability Composition Analysis (2020–2025)

This chart breaks down Sinotherapeutics Inc. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Sinotherapeutics Inc. A assets under control.

Liquidity & Leverage Metrics

Sinotherapeutics Inc. A Total Liabilities Ratios Explained

Sinotherapeutics Inc. A total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	10.98	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.11	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.10	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Sinotherapeutics Inc. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Sinotherapeutics Inc. A (2020–2025)

The table below shows the annual total liabilities of Sinotherapeutics Inc. A from 2020 to 2025.

Year	Total Liabilities	Change
2025-12-31	CN¥146.12 Million ≈ $21.38 Million	-18.96%
2024-12-31	CN¥180.30 Million ≈ $26.38 Million	+19.12%
2023-12-31	CN¥151.36 Million ≈ $22.15 Million	-2.38%
2022-12-31	CN¥155.05 Million ≈ $22.69 Million	-3.47%
2021-12-31	CN¥160.62 Million ≈ $23.50 Million	-11.14%
2020-12-31	CN¥180.76 Million ≈ $26.45 Million	--

About Sinotherapeutics Inc. A

SHG:688247 China Drug Manufacturers - Specialty & Generic

Market Cap

$529.38 Million

CN¥3.62 Billion CNY

Market Cap Rank

#11577 Global

#3277 in China

Share Price

CN¥7.98

Change (1 day)

-2.68%

52-Week Range

CN¥7.26 - CN¥11.28

All Time High

CN¥25.98